Sodium glucose co-transporter 2 (SGLT2) inhibitors were originally developed to treat hyperglycaemia in patients with type 2 diabetes (T2D) and became further a cornerstone of treating patients with chronic heart failure (CHF) [1–4]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.